S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

NASDAQ:GOSS - Gossamer Bio Stock Price, Forecast & News

$14.34
-0.66 (-4.40 %)
(As of 01/20/2020 10:44 AM ET)
Today's Range
$14.34
Now: $14.34
$15.26
50-Day Range
$13.98
MA: $18.78
$26.69
52-Week Range
$13.12
Now: $14.34
$27.15
Volume238,879 shs
Average Volume401,788 shs
Market Capitalization$947.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GOSS
CUSIPN/A
CIKN/A
Phone858-922-0718

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-146,970,000.00

Miscellaneous

Employees118
Market Cap$947.01 million
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

How were Gossamer Bio's earnings last quarter?

Gossamer Bio Inc (NASDAQ:GOSS) issued its earnings results on Tuesday, November, 12th. The company reported ($0.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.70) by $0.10. View Gossamer Bio's Earnings History.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Gossamer Bio.

What price target have analysts set for GOSS?

7 brokerages have issued 1 year price objectives for Gossamer Bio's stock. Their forecasts range from $25.00 to $32.00. On average, they anticipate Gossamer Bio's share price to reach $29.17 in the next year. This suggests a possible upside of 103.4% from the stock's current price. View Analyst Price Targets for Gossamer Bio.

What is the consensus analysts' recommendation for Gossamer Bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gossamer Bio.

Has Gossamer Bio been receiving favorable news coverage?

Headlines about GOSS stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gossamer Bio earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Gossamer Bio.

Are investors shorting Gossamer Bio?

Gossamer Bio saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 4,380,000 shares, an increase of 21.0% from the December 15th total of 3,620,000 shares. Based on an average daily volume of 593,000 shares, the short-interest ratio is currently 7.4 days. Currently, 10.2% of the shares of the company are sold short. View Gossamer Bio's Current Options Chain.

Who are some of Gossamer Bio's key competitors?

What other stocks do shareholders of Gossamer Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Tcr2 Therapeutics (TCRR), Alnylam Pharmaceuticals (ALNY), Lumentum (LITE) and Corning (GLW).

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the folowing people:
  • Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)
  • Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)
  • Mr. Bryan Giraudo, Chief Financial Officer (Age 43)
  • Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)
  • Dr. Jakob Dupont, Chief Medical Officer (Age 54)

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different of institutional and retail investors. Top institutional investors include Alpine Global Management LLC (0.03%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian. View Institutional Ownership Trends for Gossamer Bio.

Which major investors are buying Gossamer Bio stock?

GOSS stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox and Waage Christian. View Insider Buying and Selling for Gossamer Bio.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $14.34.

How big of a company is Gossamer Bio?

Gossamer Bio has a market capitalization of $947.01 million. The company earns $-146,970,000.00 in net income (profit) each year or ($22.59) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe.View Additional Information About Gossamer Bio.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is http://www.gossamerbio.com/.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.


MarketBeat Community Rating for Gossamer Bio (NASDAQ GOSS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote "Outperform" if you believe GOSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel